/Bio-Techne%20Corp%20logo%20and%20data-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Bio-Techne Corporation (TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets. Valued at $9.3 billion by market cap, the company specializes in proteins, cytokines, growth factors, immunoassays and small molecules. The leading life sciences reagents and instruments company is expected to announce its fiscal first-quarter earnings for 2026 in the near term.
Ahead of the event, analysts expect TECH to report a profit of $0.37 per share on a diluted basis, unchanged from the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.